BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters

Cancer Research

Volumn 71, Issue 9, 2011, Pages 3422-3431

  Calvo, Verónica ^a,b   Beato, Miguel ^a  

^a CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^b ALBERT EINSTEIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; HISTONE H2A; PROGESTERONE; PROGESTERONE RECEPTOR; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; EPIGENETICS; GENE SILENCING; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN DEGRADATION; UBIQUITINATION;

BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PROGESTERONE; RECEPTORS, PROGESTERONE; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; UBIQUITINATION;

EID: 79955492033     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3670     Document Type: Article

References (43)

1. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-89.
2. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-65. (Pubitemid 35154140)
3. Friedman LS, Ostermeyer EA, Lynch ED, Szabo CI, Anderson LA, Dowd P, et al. The search for BRCA1. Cancer Res 1994;54:6374-82.
4. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 2001;276:14537-40.
5. Baer R, Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 2002;12:86-91. (Pubitemid 34094995)
6. Horwitz AA, Affar el B, Heine GF, Shi Y, Parvin JD. A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase. Proc Natl Acad Sci U S A 2007;104:6614-19.
7. Starita LM, Horwitz AA, Keogh MC, Ishioka C, Parvin JD, Chiba N. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. J Biol Chem 2005;280:24498-505. (Pubitemid 40934535)
8. Vicent GP, Ballaré C, Nacht AS, Clausell J, Subtil- Rodríguez A, Quiles I, et al. Induction of progesterone target genes requires activation of Erk and Msk kinases and phosphorylation of histone H3. Mol Cell 2006;24:367-81. (Pubitemid 44649285)
9. Moore MR, Spence JB, Kiningham KK, Dillon JL. Progestin inhibition of cell death in human breast cancer cell lines. J Steroid Biochem Mol Biol 2006;98:218-27. (Pubitemid 43344251)
10. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, O'Malley BW, et al. Progesterone involvement in breast development and tumorigenesis - as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 2003;68:779-87.
11. Zheng L, Annab LA, Afshari CA, Lee WH, Boyer TG. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci U S A 2001;98:9587-92. (Pubitemid 32769347)
12. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999;284:1354-56. (Pubitemid 29289660)
13. Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth PA, et al. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 2006;20:14-34. (Pubitemid 43011667)
14. Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003;77:8957-61. (Pubitemid 36936105)
15. Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat Protoc 2007;2:1445-57. (Pubitemid 46952324)
16. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11:1475-89.
17. Strutt H, Paro R. Mapping DNA target sites of chromatin proteins in vivo by formaldehyde crosslinking. Methods Mol Biol 1999;119: 455-67.
18. Wu-Baer F, Lagrazon K, Yuan W, Baer R. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J Biol Chem 2003;278: 34743-46. (Pubitemid 37102231)
19. Di Croce L, Koop R, Venditti P, Westphal HM, Nightingale KP, Corona DF, et al. Two-step synergism between the progesterone receptor and the DNA-binding domain of nuclear factor 1 on MMTV minichromosomes. Mol Cell 1999;4:45-54. (Pubitemid 29386130)
20. Quiles I, Millán-Ariño L, Subtil-Rodríguez A, Miñana B, Spinedi N, Ballaré C, et al. Mutational analysis of progesterone receptor functional domains in stable cell lines delineates sets of genes regulated by different mechanisms. Mol Endocrinol 2009;23:809-26.
21. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci U S A 2000;97:1032-37. (Pubitemid 30080807)
22. Clemm DL, Sherman L, Boonyaratanakornkit V, Schrader WT, Weigel NL, Edwards DP, et al. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol 2000;14: 52-65. (Pubitemid 32260327)
23. Christensen DE, Klevit RE. Dynamic interactions of proteins in complex networks: identifying the complete set of interacting E2s for functional investigation of E3-dependent protein ubiquitination. FEBS J 2009;276:5381-89.
24. Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D, Fukuda M, et al. Binding and recognition in the assembly of an active BRCA1/ BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci U S A 2003;100: 5646-51. (Pubitemid 36576862)
25. Truss M, Bartsch J, Schelbert A, Hache RJ, Beato M. Hormone induces binding of receptors and transcription factors to a rearranged nucleosome on the MMTV promoter in vivo. EMBO J 1995;14: 1737-51.
26. Klehr D, Maass K, Bode J. Scaffold-attached regions from the human interferon beta domain can be used to enhance the stable expression of genes under the control of various promoters. Biochemistry 1991;30:1264-70.
27. Pina B, Bruggemeier U, Beato M. Nucleosome positioning modulates accessibility of regulatory proteins to the mouse mammary tumor virus promoter. Cell 1990;60:719-31.
28. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9:1603-14.
29. Subtil-Rodriguez A, Millan-Arino L, Quiles I, Ballare C, Beato M, Jordan A. Progesterone induction of the 11beta-hydroxysteroid dehydrogenase type 2 promoter in breast cancer cells involves coordinated recruitment of STAT5A and progesterone receptor to a distal enhancer and polymerase tracking. Mol Cell Biol 2008;28:3830-49. (Pubitemid 351732916)
30. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005;20:845-54. (Pubitemid 41814874)
31. Zhou W, Zhu P, Wang J, Pascual G, Ohgi KA, Lozach J, et al. Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation. Mol Cell 2008;29:69-80.
32. Mallery DL, Vandenberg CJ, Hiom K. Activation of the E3 ligase function of the BRCA1/BARD1 complex by polyubiquitin chains. EMBO J 2002;21:6755-62. (Pubitemid 36014547)
33. Vicent GP, Nacht AS, Smith CL, Peterson CL, Dimitrov S, Beato M. DNA instructed displacement of histones H2A and H2B at an inducible promoter. Mol Cell 2004;16:439-52. (Pubitemid 39504797)
34. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001;20:77-87. (Pubitemid 32142340)
35. Zhang PJ, Zhao J, Li HY, Man JH, He K, Zhou T, et al. CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome. EMBO J 2007;26:1831-42. (Pubitemid 46624038)
36. Hernandez MP, Chadli A, Toft DO. HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor. J Biol Chem 2002;277:11873-81. (Pubitemid 34952744)
37. Katiyar P, Ma Y, Riegel A, Fan S, Rosen EM. Mechanism of BRCA1-mediated inhibition of progesterone receptor transcriptional activity. Mol Endocrinol 2009;23:1135-46.
38. Wen J, Li R, Lu Y, Shupnik MA. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene 2009;28:575-86.
39. Thakar A, Parvin JD, Zlatanova J. BRCA1/BARD1 E3 ubiquitin ligase can modify histones H2A and H2B in the nucleosome particle. J Biomol Struct Dyn 2010;27:399-406.
40. LaMarca HL, Rosen JM. Minireview: hormones and mammary cell fate - what will I become when I grow up? Endocrinology 2008;149: 4317-21.
41. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997;57:4987-91. (Pubitemid 27498105)
42. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91: 1475-79. (Pubitemid 29424552)
43. Poole AJ, Li Y, Kim Y, Lin SC, Lee WH, Lee EY. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006;314:1467-70. (Pubitemid 44871955)